◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › CRL

Charles River Laboratories (CRL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Life Sciences Tools & Services · DATA UPDATED 2026-07-19

Charles River Laboratories (CRL) operates in the Life Sciences Tools & Services industry and is headquartered in Wilmington, United States with about 18,300 employees. Its market capitalization is roughly $11 billion. In the fiscal year ended 2025-12-31, CRL reported $4.0B in revenue and ($144M) in net income.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.

Interactive charts & full statements → Open the CRL valuation workbench →

CRL Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$4.0B	$4.0B	$4.0B	$4.1B	$4.0B	$3.5B	$2.9B	$2.6B	$2.3B	$1.9B	$1.7B	$1.4B	$1.3B	$1.2B	$1.1B	$1.1B	$1.1B	$1.2B	$1.3B	$1.2B	$1.1B
Gross Profit	$1.3B	$1.2B	$1.3B	$1.5B	$1.5B	$1.3B	$1.1B	$958M	$840M	$701M	$644M	$531M	$473M	$395M	$392M	$402M	$385M	$423M	$511M	$478M	$407M
Gross Margin %	31.9%	30.5%	32.9%	36.4%	36.8%	37.7%	36.7%	36.6%	37.1%	37.7%	38.3%	39.0%	36.4%	33.9%	34.7%	35.2%	34.0%	35.2%	38.0%	38.9%	38.4%
Operating Income (EBIT)	$474M	$508M	$227M	$617M	$651M	$590M	$433M	$351M	$331M	$288M	$238M	$206M	$178M	$151M	$166M	$174M	($299M)	$170M	($450M)	$227M	$188M
Operating Margin %	11.8%	12.7%	5.6%	14.9%	16.4%	16.7%	14.8%	13.4%	14.6%	15.5%	14.1%	15.1%	13.7%	13.0%	14.7%	15.2%	-26.3%	14.1%	-33.5%	18.5%	17.8%
Net Income	($185M)	($144M)	$10M	$475M	$486M	$391M	$364M	$252M	$226M	$123M	$155M	$149M	$127M	$103M	$97M	$110M	($337M)	$114M	($522M)	$154M	($56M)
Net Margin %	-4.6%	-3.6%	0.2%	11.5%	12.2%	11.0%	12.5%	9.6%	10.0%	6.6%	9.2%	10.9%	9.8%	8.8%	8.6%	9.6%	-29.7%	9.5%	-38.8%	12.6%	-5.3%
EBITDA	$291M	$411M	$581M	$1.0B	$986M	$820M	$768M	$563M	$507M	$458M	$377M	$305M	$286M	$256M	$244M	$260M	($205M)	$263M	($356M)	$322M	$273M
Earnings Per Share (EPS)	$-3.76	$-2.91	$0.20	$9.22	$9.48	$7.60	$7.20	$5.07	$4.62	$2.54	$3.23	$3.13	$2.66	$2.12	$2.01	$2.14	$-5.38	$1.74	$-7.76	$2.25	$-0.80
Shares Outstanding (M)	49M	50M	52M	51M	51M	51M	51M	50M	49M	49M	48M	48M	48M	48M	48M	51M	63M	66M	67M	69M	70M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$996M	$994M	$1.0B	$1.0B	$984M	$1.0B	$1.0B	$1.0B
Gross Profit	$279M	$308M	$339M	$357M	$318M	$284M	$349M	$354M
Gross Margin %	28.1%	31.0%	33.7%	34.6%	32.3%	28.3%	34.6%	34.5%
Operating Income (EBIT)	$120M	$120M	$134M	$100M	$75M	($168M)	$117M	$152M
Operating Margin %	12.0%	12.1%	13.3%	9.7%	7.6%	-16.7%	11.6%	14.8%
Net Income	($15M)	($277M)	$54M	$52M	$25M	($216M)	$69M	$90M
Net Margin %	-1.5%	-27.8%	5.4%	5.1%	2.6%	-21.5%	6.8%	8.8%
EBITDA	$64M	($192M)	$198M	$221M	$184M	($86M)	$210M	$239M
Earnings Per Share (EPS)	$-0.30	$-5.62	$1.10	$1.06	$0.50	$-4.22	$1.33	$1.74
Shares Outstanding (M)	49M	49M	49M	49M	51M	51M	52M	52M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRL Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$607M	$738M	$735M	$684M	$620M	$761M	$547M	$481M	$441M	$316M	$298M	$286M	$251M	$207M	$208M	$205M	$169M	$225M	$280M	$284M	$164M
Capital Expenditures (CapEx)	$216M	$219M	$233M	$319M	$325M	$229M	$167M	$141M	$140M	$82M	$55M	$63M	$57M	$39M	$48M	$49M	$43M	$80M	$197M	$227M	$182M
Free Cash Flow (FCF)	$391M	$518M	$502M	$365M	$295M	$532M	$380M	$340M	$301M	$234M	$243M	$223M	$194M	$168M	$160M	$156M	$126M	$145M	$83M	$57M	($17M)
FCF Margin %	9.7%	12.9%	12.4%	8.8%	7.4%	15.0%	13.0%	13.0%	13.3%	12.6%	14.4%	16.4%	15.0%	14.4%	14.2%	13.7%	11.1%	12.1%	6.2%	4.7%	-1.6%
Dividends Paid	—	—	—	$26M	—	$46M	$47M	$35M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	$2M	$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$41M	$148M	$214M	$205M	$172M	$159M	$252M	$194M
Capital Expenditures (CapEx)	$56M	$89M	$36M	$35M	$59M	$76M	$39M	$39M
Free Cash Flow (FCF)	($15M)	$59M	$178M	$169M	$112M	$84M	$213M	$154M
FCF Margin %	-1.5%	5.9%	17.7%	16.4%	11.4%	8.3%	21.1%	15.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRL Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$7.7B	$7.1B	$7.5B	$8.2B	$7.6B	$7.0B	$5.5B	$4.7B	$3.9B	$2.9B	$2.7B	$2.1B	$1.9B	$1.6B	$1.6B	$1.6B	$1.7B	$2.2B	$2.2B	$2.8B	$2.6B
Cash & Cash Equivalents	$192M	$214M	$195M	$277M	$234M	$245M	$228M	$238M	$195M	$164M	$118M	$118M	$160M	$156M	$110M	$69M	$179M	$183M	$244M	$225M	$175M
Total Liabilities	$4.7B	$3.9B	$4.0B	$4.5B	$4.6B	$4.4B	$3.3B	$3.0B	$2.5B	$1.9B	$1.9B	$1.3B	$1.2B	$980M	$983M	$1.0B	$1.0B	$830M	$960M	$942M	$953M
Total Debt (Short + Long-Term)	$2.7B	$2.2B	$2.4B	$3.1B	$2.8B	$2.7B	$2.0B	$1.9B	$1.7B	$1.1B	$1.2B	$863M	$778M	$664M	$667M	$718M	$701M	$508M	$576M	$510M	$572M
Total Shareholders' Equity	$2.9B	$3.2B	$3.5B	$3.6B	$3.0B	$2.5B	$2.1B	$1.6B	$1.3B	$1.0B	$837M	$733M	$672M	$641M	$601M	$527M	$687M	$1.4B	$1.2B	$1.9B	$1.6B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRL viewer.

Other Companies in Life Sciences Tools & Services

WAT · Waters Corporation — $37 billion
IQV · IQVIA — $35 billion
MTD · Mettler Toledo — $27 billion
TECH · Bio-Techne — $11 billion
TMO · Thermo Fisher Scientific — $211 billion
DHR · Danaher Corporation — $135 billion
A · Agilent Technologies — $39 billion

← CRK All stocks CRM →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.